Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease

Abstract

Sex and ethnicity are associated with relapsing MOGAD. Use of rituximab or IVIG therapy shortly after onset is associated with a lower risk of the second event. Preventive treatment after a first event could be considered for those with a higher relapse risk.